Product Code: A11789
The global monoclonal antibodies market was valued at $146,642 million in 2020, and is projected to reach $390,582 million by 2030, registering a CAGR of 10.2% from 2021 to 2030.
Monoclonal antibodies (mAb) are the antibodies which are developed in a laboratory from clone of a single B-cell. These antibodies recognize & attach to a specific receptor present on the surface of cells. The monoclonal antibodies are similar in nature, technically characterized as identical immunoglobulin (Ig). Moreover, these are utilized to detect numerous disease agents and for diagnostic indications. Furthermore, monoclonal antibodies are used in the treatment of autoimmune diseases, inflammatory diseases, infectious diseases, and others.
The growth of the monoclonal antibodies market is driven by rise in prevalence of cancer and other chronic diseases, increase in government funding for cancer research and technology development, and surge in adoption of humanized monoclonal antibodies (mAbs) in the treatment of several diseases including inflammatory, cancer, and autoimmune diseases. In addition, rise in demand for personalized medicines, increase in development of therapeutic monoclonal antibodies, and surge in research collaborations for the development of robust drugs pipeline drives the growth of the market. Moreover, increase in government support in infection control & management, rise in patient awareness regarding applications of murine monoclonal antibodies therapy, increase in number of clinical trials, and introduction of low-priced biosimilar monoclonal antibodies are the other factors that boost the growth of the market. However, poor demand in underdeveloped countries is expected to restrain the growth of the monoclonal antibodies market. Conversely, growth avenues in emerging markets are expected to offer lucrative opportunities during the forecast period.
The monoclonal antibodies market is segmented into source, indication, end user, and region. On the basis of source, the market is categorized into murine, chimeric, humanized, and human. By indication, the market is divided into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others. The cancer segment is further classified into breast cancer, colorectal cancer, lung cancer, ovarian cancer, and others. By end user, the market is fragmented into hospitals, research institutes, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of four regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Source
- Murine
- Chimeric
- Humanized
- Human
By Indication
- Cancer
- Breast cancer
- Colorectal cancer
- Lung cancer
- Ovarian cancer
- Others
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
- Others
By End User
- Hospitals
- Research Institutes
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Abbott Laboratories
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Eli Lilly
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis
- Pfizer
- LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
- Boehringer Ingelheim Pharmaceuticals
- AstraZeneca
- Teva Pharmaceutical Industries
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key Benefits for Stakeholders
- 1.3.Key market segments
- 1.3.1.List of key players profiled in the report
- 1.4.Research methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.2.2.Top winning strategies
- 3.3.Porter's five force analysis
- 3.4.Top player positioning, 2020
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.1.1.Rise in prevalence of various cancer types
- 3.5.1.2.Increase in demand of cost-efficient biosimilar monoclonal antibodies
- 3.5.1.3.Upsurge in likelihood of epidemic or pandemic outbreaks
- 3.5.2.Restraint
- 3.5.2.1.Poor demand in underdeveloped countries
- 3.5.3.Opportunities
- 3.5.3.1.Growth opportunities in emerging markets
- 3.5.4.Impact analysis
- 3.6.Covid-19 Impact analysis on monoclonal antibodies market
CHAPTER 4:MONOCLONAL ANTIBODIES MARKET, BY SOURCE
- 4.1.Overview
- 4.1.1.Market size and forecast
- 4.2.Murine
- 4.2.1.Key market trends, growth factors, and opportunities
- 4.2.2.Market size and forecast, by region
- 4.2.3.Market analysis, by country
- 4.3.Chimeric
- 4.3.1.Key market trends, growth factors, and opportunities
- 4.3.2.Market size and forecast, by region
- 4.3.3.Market analysis, by country
- 4.4.Humanized
- 4.4.1.Key market trends, growth factors, and opportunities
- 4.4.2.Market size and forecast, by region
- 4.4.3.Market analysis, by country
- 4.5.Human
- 4.5.1.Key market trends, growth factors, and opportunities
- 4.5.2.Market size and forecast, by region
- 4.5.3.Market analysis, by country
CHAPTER 5:MONOCLONAL ANTIBODIES MARKET, BY INDICATION
- 5.1.Overview
- 5.1.1.Market size and forecast
- 5.2.Cancer
- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country
- 5.2.3.Market size and forecast, by type
- 5.2.3.1.Breast cancer
- 5.2.3.1.1.Market size and forecast
- 5.2.3.2.Colorectal cancer
- 5.2.3.2.1.Market size and forecast
- 5.2.3.3.Lung cancer
- 5.2.3.3.1.Market size and forecast
- 5.2.3.4.Ovarian cancer
- 5.2.3.4.1.Market size and forecast
- 5.2.3.5.Others
- 5.2.3.5.1.Market size and forecast
- 5.3.Autoimmune diseases
- 5.3.1.Market size and forecast, by region
- 5.3.2.Market analysis, by country
- 5.4.Inflammatory diseases
- 5.4.1.Market size and forecast, by region
- 5.4.2.Market analysis, by country
- 5.5.Infectious diseases
- 5.5.1.Market size and forecast, by region
- 5.5.2.Market analysis, by country
- 5.6.Others
- 5.6.1.Market size and forecast, by region
- 5.6.2.Market analysis, by country
CHAPTER 6:MONOCLONAL ANTIBODIES MARKET, BY END USER
- 6.1.Overview
- 6.1.1.Market size and forecast
- 6.2.Hospitals
- 6.2.1.Market size and forecast, by region
- 6.2.2.Market analysis, by country
- 6.3.Research institutes
- 6.3.1.Market size and forecast, by region
- 6.3.2.Market analysis, by country
- 6.4.Others
- 6.4.1.Market size and forecast, by region
- 6.4.2.Market analysis, by country
CHAPTER 7:MONOCLONAL ANTIBODIES MARKET, BY REGION
- 7.1.Overview
- 7.1.1.Market size and forecast
- 7.2.North America
- 7.2.1.Key market trends, growth factors, and opportunities
- 7.2.2.Market size and forecast, by country
- 7.2.2.1.U.S.
- 7.2.2.1.1.U.S. monoclonal antibodies market, by source
- 7.2.2.1.2.U.S. monoclonal antibodies market, by indication
- 7.2.2.1.3.U.S. monoclonal antibodies market, by end user
- 7.2.2.2.Canada
- 7.2.2.2.1.Canada monoclonal antibodies market, by source
- 7.2.2.2.2.Canada monoclonal antibodies market, by indication
- 7.2.2.2.3.Canada monoclonal antibodies market, by end user
- 7.2.2.3.Mexico
- 7.2.2.3.1.Mexico monoclonal antibodies market, by source
- 7.2.2.3.2.Mexico monoclonal antibodies market, by indication
- 7.2.2.3.3.Mexico monoclonal antibodies market, by end user
- 7.2.3.North America market size and forecast, by source
- 7.2.4.North America market size and forecast, by indication
- 7.2.5.North America market size and forecast, by end user
- 7.3.Europe
- 7.3.1.Key market trends, growth factors, and opportunities
- 7.3.2.Market size and forecast, by country
- 7.3.2.1.Germany
- 7.3.2.1.1.Germany monoclonal antibodies market, by source
- 7.3.2.1.2.Germany monoclonal antibodies market, by indication
- 7.3.2.1.3.Germany monoclonal antibodies market, by end user
- 7.3.2.2.France
- 7.3.2.2.1.France monoclonal antibodies market, by source
- 7.3.2.2.2.France monoclonal antibodies market, by indication
- 7.3.2.2.3.France monoclonal antibodies market, by end user
- 7.3.2.3.UK
- 7.3.2.3.1.UK monoclonal antibodies market, by source
- 7.3.2.3.2.UK monoclonal antibodies market, by indication
- 7.3.2.3.3.UK monoclonal antibodies market, by end user
- 7.3.2.4.Italy
- 7.3.2.4.1.Italy monoclonal antibodies market, by source
- 7.3.2.4.2.Italy monoclonal antibodies market, by indication
- 7.3.2.4.3.Italy monoclonal antibodies market, by end user
- 7.3.2.5.Spain
- 7.3.2.5.1.Spain monoclonal antibodies market, by source
- 7.3.2.5.2.Spain monoclonal antibodies market, by indication
- 7.3.2.5.3.Spain monoclonal antibodies market, by end user
- 7.3.2.6.Rest of Europe
- 7.3.2.6.1.Rest of Europe monoclonal antibodies market, by source
- 7.3.2.6.2.Rest of Europe monoclonal antibodies market, by indication
- 7.3.2.6.3.Rest of Europe monoclonal antibodies market, by end user
- 7.3.3.Europe market size and forecast, by source
- 7.3.4.Europe market size and forecast, by indication
- 7.3.5.Europe market size and forecast, by end user
- 7.4.Asia-Pacific
- 7.4.1.Key market trends, growth factors, and opportunities
- 7.4.2.Market size and forecast, by country
- 7.4.2.1.Japan
- 7.4.2.1.1.Japan monoclonal antibodies market, by source
- 7.4.2.1.2.Japan monoclonal antibodies market, by indication
- 7.4.2.1.3.Japan monoclonal antibodies market, by end user
- 7.4.2.2.China
- 7.4.2.2.1.China monoclonal antibodies market, by source
- 7.4.2.2.2.China monoclonal antibodies market, by indication
- 7.4.2.2.3.China monoclonal antibodies market, by end user
- 7.4.2.3.Australia
- 7.4.2.3.1.Australia monoclonal antibodies market, by source
- 7.4.2.3.2.Australia monoclonal antibodies market, by indication
- 7.4.2.3.3.Australia monoclonal antibodies market, by end user
- 7.4.2.4.India
- 7.4.2.4.1.India monoclonal antibodies market, by source
- 7.4.2.4.2.India monoclonal antibodies market, by indication
- 7.4.2.4.3.India monoclonal antibodies market, by end user
- 7.4.2.5.South Korea
- 7.4.2.5.1.South Korea monoclonal antibodies market, by source
- 7.4.2.5.2.South Korea monoclonal antibodies market, by indication
- 7.4.2.5.3.South Korea monoclonal antibodies market, by end user
- 7.4.2.6.Rest of Asia-Pacific
- 7.4.2.6.1.Rest of Asia-Pacific monoclonal antibodies market, by source
- 7.4.2.6.2.Rest of Asia-Pacific monoclonal antibodies market, by indication
- 7.4.2.6.3.Rest of Asia-Pacific monoclonal antibodies market, by end user
- 7.4.3.Asia-Pacific market size and forecast, by source
- 7.4.4.Asia-Pacific market size and forecast, by indication
- 7.4.5.Asia-Pacific market size and forecast, by end user
- 7.5.LAMEA
- 7.5.1.Key market trends, growth factors, and opportunities
- 7.5.2.Market size and forecast, by country
- 7.5.2.1.Brazil
- 7.5.2.1.1.Brazil monoclonal antibodies market, by source
- 7.5.2.1.2.Brazil monoclonal antibodies market, by indication
- 7.5.2.1.3.Brazil monoclonal antibodies market, by end user
- 7.5.2.2.Saudi Arabia
- 7.5.2.2.1.Saudi Arabia monoclonal antibodies market, by source
- 7.5.2.2.2.Saudi Arabia monoclonal antibodies market, by indication
- 7.5.2.2.3.Saudi Arabia monoclonal antibodies market, by end user
- 7.5.2.3.South Africa
- 7.5.2.3.1.South Africa monoclonal antibodies market, by source
- 7.5.2.3.2.South Africa monoclonal antibodies market, by indication
- 7.5.2.3.3.South Africa monoclonal antibodies market, by end user
- 7.5.2.4.Rest of LAMEA
- 7.5.2.4.1.Rest of LAMEA monoclonal antibodies market, by source
- 7.5.2.4.2.Rest of LAMEA monoclonal antibodies market, by indication
- 7.5.2.4.3.Rest of LAMEA monoclonal antibodies market, by end user
- 7.5.3.LAMEA market size and forecast, by source
- 7.5.4.LAMEA market size and forecast, by indication
- 7.5.5.LAMEA market size and forecast, by end user
CHAPTER 8:COMPANY PROFILES
- 8.1.Abbott Laboratories
- 8.1.1.Company overview
- 8.1.2.Company snapshot
- 8.1.3.Operating business segments
- 8.1.4.Product portfolio
- 8.1.5.Business performance
- 8.2.Amgen Inc
- 8.2.1.Company overview
- 8.2.2.Company snapshot
- 8.2.3.Operating business segments
- 8.2.4.Product Portfolio
- 8.2.5.Business performance
- 8.2.6.Key strategic moves and developments
- 8.3.AstraZeneca PLC.
- 8.3.1.Company overview
- 8.3.2.Company snapshot
- 8.3.3.Operating business segments
- 8.3.4.Product Portfolio
- 8.3.5.Business performance
- 8.4.Bayer AG.
- 8.4.1.Company overview
- 8.4.2.Company snapshot
- 8.4.3.Operating business segments
- 8.4.4.Product Portfolio
- 8.4.5.Business performance
- 8.5.Eli Lily and Company.
- 8.5.1.Company overview
- 8.5.2.Company snapshot
- 8.5.3.Operating business segments
- 8.5.4.Product portfolio
- 8.5.5.Business performance
- 8.5.6.Key strategic moves and developments
- 8.6.GlaxoSmithKline plc
- 8.6.1.Company overview
- 8.6.2.Company snapshot
- 8.6.3.Operating business segments
- 8.6.4.Product portfolio
- 8.6.5.Business performance
- 8.6.6.Key strategic moves and developments
- 8.7.Johnson & Johnson
- 8.7.1.Company overview
- 8.7.2.Company snapshot
- 8.7.3.Operating business segments
- 8.7.4.Product portfolio
- 8.7.5.Business performance
- 8.7.6.Key strategic moves and developments
- 8.8.Merck & Co., Inc.
- 8.8.1.Company overview
- 8.8.2.Company snapshot
- 8.8.3.Operating business segments
- 8.8.4.Product portfolio
- 8.8.5.Business performance
- 8.9.Novartis AG
- 8.9.1.Company overview
- 8.9.2.Company snapshot
- 8.9.3.Operating business segments
- 8.9.4.Product portfolio
- 8.9.5.Business performance
- 8.9.6.Key strategic moves and developments
- 8.10.PFIZER INC.
- 8.10.1.Company overview
- 8.10.2.Company snapshot
- 8.10.3.Operating business segments
- 8.10.4.Product portfolio
- 8.10.5.Business performance
- 8.10.6.Key strategic moves and developments